Details for New Drug Application (NDA): 202319
✉ Email this page to a colleague
The generic ingredient in LANSOPRAZOLE is amoxicillin; clarithromycin; lansoprazole. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; lansoprazole profile page.
Summary for 202319
Tradename: | LANSOPRAZOLE |
Applicant: | Perrigo R And D |
Ingredient: | lansoprazole |
Patents: | 0 |
Pharmacology for NDA: 202319
Mechanism of Action | Proton Pump Inhibitors |
Physiological Effect | Inhibition Gastric Acid Secretion |
Medical Subject Heading (MeSH) Categories for 202319
Suppliers and Packaging for NDA: 202319
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LANSOPRAZOLE | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 202319 | ANDA | L. Perrigo Company | 0113-0117 | 0113-0117-01 | 1 BOTTLE in 1 CARTON (0113-0117-01) / 14 CAPSULE, DELAYED RELEASE in 1 BOTTLE |
LANSOPRAZOLE | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 202319 | ANDA | L. Perrigo Company | 0113-0117 | 0113-0117-02 | 2 BOTTLE in 1 CARTON (0113-0117-02) / 14 CAPSULE, DELAYED RELEASE in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | OTC | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | 15MG | ||||
Approval Date: | May 18, 2012 | TE: | RLD: | No |
Complete Access Available with Subscription